Skip to main content
SpringerLink
Log in

Prostaglandins, Thromboxanes and Platelet Function

  • Conference paper
Prostacyclin and Its Stable Analogue Iloprost

Abstract

During the 1960s it was observed that certain long-chain saturated or unsaturated fatty acids induced aggregation of washed human platelets, but the physiological significance of this phenomenon was questioned [44].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aharony D, Smith JB, Silver MJ (1982) Regulation of arachidonate-induced platelet aggregation by the lipoxygenase product 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta 718: 193–200

    Article  PubMed  CAS  Google Scholar 

  2. Bertelé V, Cerletti C, Schieppati A, Di Minno G, de Gaetano G (1981) Inhibition of thromboxane synthetase does not necessarily prevent platelet aggregation. Lancet 1: 1057–1058

    Article  Google Scholar 

  3. Bertelé V, de Gaetano G (1982) Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin. Euro J Pharmacol 85: 331–333

    Article  Google Scholar 

  4. Bertelé V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, de Gaetano G (1984) Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclo-oxygenase products. Blood 63: 1460–1466

    PubMed  Google Scholar 

  5. Bertelé V, Falanga A, Tomasiak M, Dejana E, Cerletti C, de Gaetano G (1983) Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the “aspirin dilemma”. Science 220: 517–519

    Article  PubMed  Google Scholar 

  6. Bertelé V, Falanga A, Tomasiak M, Cerletti C, de Gaetano G (1984) SQ 22 536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor. Thromb Haemost 51: 125–128

    PubMed  Google Scholar 

  7. Bertelé V, Stemerman H, Shafer A, Adelman B, Smith M, Fuhro R, Salzman EW (1985) Refractoriness of platelets to prostaglandins after infusion in rabbits. J Lab Clin Med 106: 551–561

    PubMed  Google Scholar 

  8. Buchanan MR, Butt RW, Magas Z, Van Ryn J, Hirsh J, Nazir DJ (1985) Endothelial cells produce a lipoxygenase derived chemo-repellant which influences platelet/endothelial cell interactions — effect of aspirin and salicylate. Thromb Haemost 53: 306–311

    PubMed  CAS  Google Scholar 

  9. Buchanan MR, Dejana E, Cazenave JP, Richardson M, Mustard JF, Hirsch J (1980) Differences in inhibition of PGI2 production by aspirin in rabbit artery and vein segments. Thromb Res 20: 447–460

    Article  PubMed  CAS  Google Scholar 

  10. Burch JW, Stanford N, Majerus PW (1978) Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61: 314–319

    Article  PubMed  CAS  Google Scholar 

  11. Cerletti C, Bonati M, Del Maschio A, Galletti F, Dejana E, Tognoni G, de Gaetano G (1984) Plasma levels of salicylate and aspirin in healthy volunteers: relevance to drug interaction on platelet function. J Lab Clin Med 103: 869–877

    PubMed  CAS  Google Scholar 

  12. Cerletti C, Gambino MC, Garattini S, de Gaetano G (1985) Differential inhibition of prostacyclin synthesis in portal vein and aorta after intraduodenal (i.D.), but not i.V. Aspirin administration. Blood 66 Suppl 1: 302A

    Google Scholar 

  13. Cerletti C, Latini R, Dejana E, Tognoni G, Garattini S, de Gaetano G (1985) Inhibition of human platelet thromboxane generation by aspirin in the absence of measurable drug levels in peripheral blood. Biochem Pharmacol 34: 1839–1841

    Article  PubMed  CAS  Google Scholar 

  14. Cerletti, C, Minoldo S, Bucchi F, Del Maschio A, de Gaetano G (1986) Requirement of ADP for arachidonic acid-induced platelet aggregation: studies with selective thromboxane-synthase inhibitors. Biochem Pharmacol 35: 1201–1203

    Article  PubMed  CAS  Google Scholar 

  15. Chiesa R, Vicari A, Mari G, Galimberti M, Di Carlo V, Pozza G (1985) Use of stable prostacyclin analogue ZK 36 374 to treat severe lower limb ischaemia. Lancet 2: 95–96

    Article  PubMed  CAS  Google Scholar 

  16. Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J (1979) The role of platelet-activating factor in platelet aggregation. Nature 279: 799–800

    Article  PubMed  CAS  Google Scholar 

  17. Chignard M, Le Couedic JP, Vargaftig BB, Benveniste J (1980) Platelet activating factor (PAF-Acether) secretion from platelets: effect of aggregating agents. Br J Haematol 46: 455–464

    Article  PubMed  CAS  Google Scholar 

  18. Claesson HE, Malmsten C (1977) On the interrelationship of prostaglandin endoperoxide G2 and cyclic nucleotides in platelet function. Eur J Biochem 76: 277–284

    Article  PubMed  CAS  Google Scholar 

  19. de Gaetano G (1981) Platelets, prostaglandins and thrombotic disorders. In: Prentice CRM (ed) Clinics in haematology. Saunders, London, pp 297–326

    Google Scholar 

  20. de Gaetano G, Bertelé V, Cerletti C, Di Minno G (1982) Prostaglandins effects on platelets. In: Wu, Ross (eds) Prostaglandins in clinical medicine. Year Book, Chicago, pp 49–74

    Google Scholar 

  21. de Gaetano G, Cerletti C, Bertelé V (1982) Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link. Lancet 2: 974–977

    Article  PubMed  Google Scholar 

  22. de Gaetano G, Cerletti C, Dejana E, Latini R (1985) Human pharmacology of platelet inhibition: implications of the salicylate-aspirin interaction. Circulation 72: 1105–1193

    Google Scholar 

  23. de Gaetano G, Donati MB, Vermylen J (1971) Some effects of indomethacin on platelet function, blood coagulation and fibrinolysis. Int Z Klin Pharmakol Ther Toxikol 5: 196–199

    PubMed  Google Scholar 

  24. Dejana E, Barbieri B, Cerletti C, Livio M, de Gaetano G (1980) Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats. Br J Haematol 46: 465–469

    CAS  Google Scholar 

  25. Dembinska-Kiec A, Kostka-Trabka E, Gryglewski RJ (1982) Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thromb Haemost 47: 190

    PubMed  CAS  Google Scholar 

  26. Di Minno G, Bertelé V, Bianchi L, Barbieri B, Cerletti C, Dejana E, de Gaetano G, Silver MJ (1981) Effect of an epoxymethano stable analogue of prostagladin endoperoxides (U-46619) on human platelets. Thromb Haemost 45: 103–106

    PubMed  Google Scholar 

  27. Di Minno G, Silver MJ, de Gaetano G (1979) Prostaglandins as inhibitors of human platelet aggregation. Br J Haematol 43: 637–647

    Article  PubMed  Google Scholar 

  28. Di Minno G, Silver MJ, de Gaetano G (1979) Ingestion of dipyridamole reduces inhibitory effect of prostacyclin on human platelets. Lancet 2: 701–702

    Article  PubMed  Google Scholar 

  29. Fitzgerald GA, Brash AR, Falardeau P, Oates JA (1981) Estimated rate of prostaglandin secretion into the circulation of normal man. J Clin Invest 68: 1272–1276

    Article  PubMed  CAS  Google Scholar 

  30. Fitzgerald GA, Brash AR, Oates J A, Pedersen AK (1983) Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 71: 1336–1343

    Article  Google Scholar 

  31. Fitzgerald GA, Oates JA, Hawiger J, Maas RL, Roberts II LJ, Lawson JA, Brash AR (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71: 676–688

    Article  PubMed  CAS  Google Scholar 

  32. Fitzpatrick DA, Bundy GL, Gorman RR, Honohan T (1978) 9,ll-Epoxyiminoprosta-5-13 dienoic acid is a thromboxane A2 antagonist in human platelets. Nature 275: 764–766

    Article  PubMed  CAS  Google Scholar 

  33. Fitzpatrick FA, Gorman RR (1978) A comparison of imidazole and 9,ll-azoprosta-5-13-dienoic acid. Two selective thromboxane synthetase inhibitors. Biochim Biophys Acta 539: 162–172

    Article  PubMed  CAS  Google Scholar 

  34. Gorman RR, Bundy GL, Peterson DC, Sun FF, Miller OV, Fitzpatrick FA (1977) Inhibition of human platelet thromboxane synthetase by 9,11 azoprosta-5,13 dienoic acid. Proc Natl Acad Sci USA 74: 4007–4011

    Article  PubMed  CAS  Google Scholar 

  35. Gordon JL, Pearson JD (1978) Effects of sulphinpyrazone and aspirin on prostaglandin I2 (prostacyclin) synthesis by endothelial cells. Br J Pharmacol 64: 481–483

    PubMed  CAS  Google Scholar 

  36. Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J (1984) BW 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man. Lancet 1: 991–994

    Article  PubMed  CAS  Google Scholar 

  37. Gresele P, Deckmyn H, Huybrechts E, Vermylen J (1984) Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochem Pharmacol 33: 2083–2088

    Article  PubMed  CAS  Google Scholar 

  38. Gresele P, Zoja C, Deckmyn H, Arnout J, Vermylen J, Verstraete M (1983) Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost 50: 852–856

    PubMed  CAS  Google Scholar 

  39. Hamberg M, Samuelsson B (1973) Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc Natl Acad Sci USA 70: 899–903

    Article  PubMed  CAS  Google Scholar 

  40. Hamberg M, Samuelsson B (1974) Prostaglandin endoperoxides. Novel transformation of arachidonic acid in human platelets. Proc Natl Acad Sci USA 71: 3400–3404

    Article  PubMed  CAS  Google Scholar 

  41. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72: 2994–2998

    Article  PubMed  CAS  Google Scholar 

  42. Hamberg M, Svensson J, Wakabayashi T, Samuelsson B (1974) Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 71: 345–349

    Article  PubMed  CAS  Google Scholar 

  43. Hanson SA, Harker LA (1985) Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sul-finpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 75: 1591–1599

    Article  PubMed  CAS  Google Scholar 

  44. Haslam RJ (1964) Role of adenosine diphosphate in the aggregation of human blood-platelets by thrombin and by fatty acids. Nature 202: 765–768

    Article  PubMed  CAS  Google Scholar 

  45. Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ (1980) Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res 20: 219–230

    Article  PubMed  CAS  Google Scholar 

  46. Jaffe EA, Weksler BB (1979) Recovery of endothelial cell prostacyclin in production after inhibition by low doses of aspirin. J Clin Invest 63: 532–535

    Article  PubMed  CAS  Google Scholar 

  47. Kam ST, Portoghese PS, Dunham EW, Gerrard JM (1979) 9,11 Azo 13-oxa 15-hydroxy-prostanoic acid: a potent thromboxane synthetase inhibitor and a PGH2/TxA2 receptor antagonist. Prostaglandins Leukotrienes Med 3: 279–290

    Google Scholar 

  48. Kloeze J (1967) Influence of prostaglandins on platelet adhesiveness and platelet aggregation. In: Bergstrom S, Sameulsson B (eds) Prostaglandins. Proceedings, 2nd Nobel Symposium, London. Interscience, pp 241–252 London

    Google Scholar 

  49. Kloeze J (1969) Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochim Biophys Acta 187: 285–292

    PubMed  CAS  Google Scholar 

  50. Korbut R, Byrska-Danek A, Gryglewski RJ (1983) Fibrinolytic activity of 6-keto-prostaglandin EA. Thromb Haemost 50: 893

    PubMed  CAS  Google Scholar 

  51. Lauri D,. Cerletti C, de Gaetano G (1985) Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways. J Lab Clin Med 105: 653–658

    Google Scholar 

  52. Le Breton GC, Venton DL, Enke SE, Halushka PV (1979) 13 Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc Natl Acad Sci USA 76: 4097–4101

    Google Scholar 

  53. Lefer AM, Smith EF III, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC (1980) Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA 77: 1706–1710

    Article  PubMed  CAS  Google Scholar 

  54. Livio M, Villa S, de Gaetano G (1980) Long-lasting inhibition of platelet prostaglandin but normal vascular prostacyclin generation following sulphinpyrazone administration to rats. J Pharm Pharmacol 32: 718–719

    Article  PubMed  CAS  Google Scholar 

  55. Macconi D, Morzenti G, Livio M, Morelli C, Cassina G, Remuzzi G (1985) Acetyl glyceryl-phosphorylcholine aggregates human platelets through two distinct pathways both dependent on arachidonic acid metabolism. Lab Invest 52: 159–168

    PubMed  CAS  Google Scholar 

  56. Maclntyre DE, Gordon JL (1977) Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins. Thromb Res 11: 705–713

    Article  Google Scholar 

  57. Masotti G, Galanti G, Poggesi L, Abbate E, Neri Serneri GG (1979) Different inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet 2: 1213–1216

    Article  PubMed  CAS  Google Scholar 

  58. Mielke CH Jr, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI (1969) The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34: 204–215

    PubMed  Google Scholar 

  59. Moncada S, Gryglewski R, Bunting S, Vane JR (1976) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an instable substance that inhibits platelet aggregation. Nature 263: 663–665

    Article  PubMed  CAS  Google Scholar 

  60. Moncada S, Korbut R (1978) Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet 1: 1286–1289

    Article  PubMed  CAS  Google Scholar 

  61. Moncada S, Vane JR (1979) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30: 293–331

    Google Scholar 

  62. Mussoni L, Carriero MR, Cerletti C, de Gaetano G (1985) Low dose aspirin does not affect vascular fibrinolytic response to venous occlusion. Blood 66 Suppl 1: 352A

    Google Scholar 

  63. Nugteren DH (1975) Arachidonate lipoxygenase in blood platelets. Biochim Biophys Acta 380: 299–307

    PubMed  CAS  Google Scholar 

  64. Nugteren DH, Hazelhof E (1973) Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 326: 448–461

    PubMed  CAS  Google Scholar 

  65. O’Brien JR (1968) Effects of salicylates on human platelets. Lancet 1: 779–783

    Article  PubMed  Google Scholar 

  66. Oelz O, Oelz R, Knapp HR, Sweetman BJ, Oates JA (1977) Biosynthesis of prostaglandin D2. 1. Formation of prostaglandin D2 by human platelets. Prostaglandins 13: 225–234

    Article  PubMed  CAS  Google Scholar 

  67. Ogletree ML, Harrisdon N, Greenberg R, Haslanger F, Nakane M (1985) Pharmacological actions of SQ 29,548. A novel selective thromboxane antagonist. J Pharmacol Exp Ther 234: 435–441

    PubMed  CAS  Google Scholar 

  68. Pareti FI, Mannucci PM, D’Angelo A, Smith JB, Sautebin L, Galli G (1980) Congenital deficiency of thromboxane and prostacyclin. Lancet 1: 898–901

    Article  PubMed  CAS  Google Scholar 

  69. Patrignani P, Filabozzi P, Catella F, Pugliese F, Patrono C (1984) Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. J Pharmacol Exp Ther 228: 472–477

    PubMed  CAS  Google Scholar 

  70. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366–1372

    Article  PubMed  CAS  Google Scholar 

  71. Pedersen AK, Fitzgerald GA (1984) Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311: 1206–1211

    Article  PubMed  CAS  Google Scholar 

  72. Pedersen AK, Fitzgerald GA (1985) Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 37: 36–42

    Article  PubMed  CAS  Google Scholar 

  73. Preston FE, Whipps S, Jackson CA, French AJ, Wyld PH, Stoddard CJ (1981) Inhibition of prostacyclin and platelet thromboxane A2, after low-dose of aspirin. N Engl J Med 304: 76–79

    Article  PubMed  CAS  Google Scholar 

  74. Rajtar G, Cerletti C, Castagnoli MN, Bertele V, de Gaetano G (1985) Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors. Biochem Pharmacol 34: 307–310

    CAS  Google Scholar 

  75. Raz A, Minkes MS, Needleman P (1977) Endoperoxides and thromboxanes. Structural determinants for platelet aggregation and vasoconstriction. Biochim Biophys Acta 488: 305–311

    PubMed  CAS  Google Scholar 

  76. Roth GJ, Majerus PW (1975) The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56: 624–632

    Article  PubMed  CAS  Google Scholar 

  77. Salzman EW (1978) Platelets, prostaglandins, and cyclic nucleotides. In: de Gaetano G, Garattini S (eds) Platelets: a multidisciplinary approach. Raven, New York, pp 227–238

    Google Scholar 

  78. Schrör K, Darius H, Matzky R, Ohlendorf R (1981) The antiplatelet and cardiovascular action of a new carbocyclin derivative (ZK 36374). Equipotent to PGI2 in vitro. Naunyn Schmiedebergs Arch Pharmacol 316: 252–255

    Article  PubMed  Google Scholar 

  79. Siebert DJ, Bochner F, Imhoff DM, Watts S, Lloyd JV, Field J, Gabb BW (1983) Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 33: 367–374

    Article  PubMed  CAS  Google Scholar 

  80. Siegl AM, Smith JB, Silver MJ, Nicolaou KC, Ahern D (1979) Selective binding site for (3H) prostacyclin on platelets. J Clin Invest 63: 215–220

    Article  PubMed  CAS  Google Scholar 

  81. Silver MJ, Smith JB, Ingerman C, Kocsis J J (1973) Arachidonic acid induces human platelet aggregation and prostaglandin formation. Prostaglandins 4: 863–875

    Article  PubMed  CAS  Google Scholar 

  82. Sinzinger HJ, Horsch AK, Silberbauer K (1983) The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease. Thromb Haemost 50: 885–887

    PubMed  CAS  Google Scholar 

  83. Sinzinger HJ, Leithner C, Silberbauer K (1984) Rebound platelet activation during continuous epoprostanol infusion. Lancet 2: 759

    Article  PubMed  CAS  Google Scholar 

  84. Sinzinger HJ, Silberbauer K, Horsch AK, Fall A (1981) Decreased sensitivity of human platelets to PGI2 during long term intra-arterial prostacyclin infusion in patients with peripheral vascular disease. A rebound phenomenon? Prostaglandins 21: 49–51

    Article  PubMed  CAS  Google Scholar 

  85. Smith JB (1982) Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase. Thromb Res 28: 477–485

    Article  PubMed  CAS  Google Scholar 

  86. Smith JB, Araki H, Lefer AM (1980) Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation 62 (Suppl 5): 19–25

    Google Scholar 

  87. Smith JB, Ingerman C, Kocsis JJ, Silver MJ (1974) Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction. J Clin Invest 53: 1468–1472

    Article  PubMed  CAS  Google Scholar 

  88. Smith JB, Ingerman CM, Silver MJ (1976) Formation of prostaglandin D2 during endoper-oxide-induced platelet aggregation. Thromb Res 9: 413–418

    Article  PubMed  CAS  Google Scholar 

  89. Smith JB, Ogletree ML, Lefer AM, Nicolaou KC (1978) Antibodies which antagonise the effects of prostacyclin. Nature 274: 64–65

    Article  PubMed  CAS  Google Scholar 

  90. Smith JB, Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol 231: 235–237

    PubMed  CAS  Google Scholar 

  91. Steer ML, MacIntyre ES, Levine L, Salzman EW (1980) Is prostacyclin a physiologically important circulating antiplatelet agent? Nature 283: 194–195

    Article  PubMed  CAS  Google Scholar 

  92. Subbarao K, Rucinski B, Rausch MA, Schmid K, Niewiarowski S (1977) Binding of dipyridamole to human platelets and to 1, acid glyco-protein and its significance for the inhibition of adenosine uptake. J Clin Invest 60: 936–943

    Article  PubMed  CAS  Google Scholar 

  93. Szczeklik A, Gryglewski RJ (1985) Prostaglandin in therapy of cardiovascular disease. Adv Prostaglandin Thromboxane Leukotriene Res 13: 345–354

    CAS  Google Scholar 

  94. Utsunomiya T, Krusz MM, Valeri CR, Shepro D, Hechtman HB (1980) Treatment of pulmonary embolism with prostacyclin. Surgery 88: 25–30

    PubMed  CAS  Google Scholar 

  95. Vane JR (1984) Prostacyclin in the cardiovascular system in health and disease. In: Schrör K (ed) Prostaglandins and other eicosanoids in the cardiovascular system. Proceedings 2nd international symposium Nürnberg-Fürth 1984. Karger, Basel, pp 7–28

    Google Scholar 

  96. Vargaftig BB, Zirinis P (1983) Platelet aggregation induced by arachidonic acid is accompanied by release of potentional inflammatory mediators distinct from PGE2 and PGF2α. Nature New Biol 244: 114–116

    Google Scholar 

  97. Vermylen J, Chamone DAF, Verstraete M (1979) Stimulation of prostacyclin release fom vessel wall by BAY g 6575, an antithrombotic compound. Lancet 1: 518–520

    Article  PubMed  CAS  Google Scholar 

  98. Villa S, de Gaetano G (1977) Prostacyclin-like activity in rat vascular tissues. Fast, long lasting inhibition by treatment with lysine acetylsalicylate. Prostaglandins 14: 1117–1124

    CAS  Google Scholar 

  99. Villa S, de Gaetano G (1979) Bleeding time in laboratory animals IV — Effects of prostacyclin, pyrimido-pyrimidine compounds and aspirin in rats —. Thromb Res 15: 727–732

    CAS  Google Scholar 

  100. Villa S, Livio M, de Gaetano G (1979) The inhibitory effect of aspirin on platelet and vascular prostaglandins in rats cannot be completely dissociated. Br J Haematol 42: 425–431

    CAS  Google Scholar 

  101. White JG, Gerrard JM (1978) Platelet morphology and the ultrastructure of regulatory mechanisms involved in platelet activation. In: de Gaetano G, Garattini S (eds) Platelets: a multidisciplinary approach. Raven, New York, pp 17–34

    Google Scholar 

  102. Whittle BJR, Moncada S, Vane JR (1978) Comparison of the effects of prostacyclin (PGI2), prostaglandin E1, and D2 on platelet aggregation in different species. Prostaglandins 16: 373–388

    Article  PubMed  CAS  Google Scholar 

  103. Willis AL, Kuhn DC (1973) A new potential mediator of arterial thrombosis whose biosynthesis is inhibited by aspirin. Prostaglandins 4: 127–130

    Article  PubMed  CAS  Google Scholar 

  104. Willis AL, Vane FM, Kuhn DC, Scott OG, Petrin M (1974) An endoperoxide aggregator (LASS), formed in platelets in response to thrombotic stimuli: purification and unique biological significance. Prostaglandins 8: 453–507

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cardiovascular Clinical Pharmacology, Mario Negri Institute for Pharmacological Research, Milano, Italy

    G. de Gaetano, V. Bertelé & C. Cerletti

Authors
  1. G. de Gaetano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Bertelé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Cerletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Copernicus Academy of Medicine, 16 GrzegĂłrzecka, 31531, Cracow, Poland

    R. J. Gryglewski

  2. Cardiovascular Pharmacology, Schering AG, Müllerstraße 170–178, 1000, Berlin 65, Germany

    G. Stock

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Springer-Verlag, Berlin Heidelberg

About this paper

Cite this paper

de Gaetano, G., Bertelé, V., Cerletti, C. (1987). Prostaglandins, Thromboxanes and Platelet Function. In: Gryglewski, R.J., Stock, G. (eds) Prostacyclin and Its Stable Analogue Iloprost. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71499-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-71499-3_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-71501-3

  • Online ISBN: 978-3-642-71499-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation